Aria Diagnostics Raises $52.7M to Commercialize Non-Invasive Trisomy Test | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) — Aria Diagnostics said today that it has raised $52.7 million in Series C funding that it will use to commercialize a prenatal test to detect fetal aneuploidies such as trisomy 21.

New investors include Meritech Capital Partners and an undisclosed mutual fund group. Existing investors Venrock and Domain Associates also participated in the round.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Journals and research funding agencies pledge to enable the sharing of Zika virus research.

In Nature this week: weighting scheme increases GWAS power, and more.

Marc Tessier-Lavigne is to be the next president of Stanford University.

Walgreens has given Theranos 30 days to fix its lab issues, the Wall Street Journal reports.

Mar
03
Sponsored by
Agilent Technologies

This webinar will discuss the use of a hybrid capture-based FFPE DNA sequencing methodology with the potential for advancing precision oncology studies.